Saturday, September 7, 2019

SESSION 1: UPPER GI
Moderator: Savita Srivastava, MD

Celiac Disease: Update on Management of Challenging Cases
Amy S. Oxentenko, MD, FACG
Explain current challenges in the care of patients with gluten sensitivity and celiac disease, and outline treatment strategies for severe and refractory patients.

Functional Dyspepsia: Getting to the Right Diagnosis and Treatment
William D. Chey, MD, FACG
Identify the epidemiology, diagnostic processes, and best practices for the management of functional dyspepsia.

Refractory GERD – Moving Beyond PPIs
David A. Leiman, MD
Discuss diagnosis and treatment of refractory heartburn and chest pain resistant to PPI therapy.

SESSION 2: PANCREAS / BILIARY
Moderator: Savita Srivastava, MD

Best Practices in EUS / FNA
Linda S. Lee, MD
Define optimal techniques and practices in EUS/FNA to improve validity and quality, including the role of contrast-enhanced EUS, on-site cytopathology, needle types, and FNA versus FNB.

Applying ACG Guidelines to Management of Pancreatic Cysts
Bryan G. Sauer, MD, MSc (Clin Res), FACG
Recognize the types of pancreatic cysts, discuss diagnostic evaluation, and examine the varied guidelines for cyst management.

Update on the Management of Necrotizing Pancreatitis
Amrita Sethi, MD
Describe the approach used to manage patients with necrotizing pancreatitis, including the role of interventional endoscopy for management of complicated cases.

SESSION 3: LIVER
Moderator: Savita Srivastava, MD

Richard K. Sterling, MD, MSc, FACG
Identify the appropriate use of non-invasive liver fibrosis tests, such as serum fibrosis assays and imaging-based elastography, in clinical practice for patients with viral hepatitis, NASH, and other chronic liver disorders.

Pearls and Pitfalls of Managing HCV Infection in Practice: Case-Based Learning
Patrick G. Northup, MD, FACG
Using a case-based format, identify patient selection criteria for treatment with DAAs, pre-treatment counseling, insurance hurdles, selection of appropriate drug regimens, drug monitoring strategies, post-treatment surveillance, and options for treatment.

Approach to Management of Solid and Cystic Liver Lesions in Non-Cirrhosis Patients
Fasiha Kanwal, MD, MSHS
Explain the diagnosis and management of solid and cystic lesions of the liver found incidentally on standard GI imaging in non-cirrhosis patients.
Addressing the Epidemic of Burnout in Gastroenterology – Finding a Path to Physical and Psychological Wellbeing
Ronald J. Vender, MD, MACG
Recognize and identify burnout predictors, describe what institutions or practices can do to mitigate burnout, and identify ways to facilitate work-life balance.

AFTERNOON BREAKOUT PRESENTATIONS

Nursing Sponsored Session – Infection Prevention: A Primer on the SGNA Position Statements and Standards of Practice
Cynthia M. Friis, MEd, BSN, RN-BC
Detail measures that can be taken to prevent infections in a GI practice.

ACG Legislative Update
Daniel J. Pambianco, MD, FACG
Discuss the current political climate and policy priorities shaping the healthcare legislative process.

SESSION 4: LOWER GI / FUNCTIONAL
Moderator: Anne G. Tuskey, MD, FACG

New Applications of the Microbiome in Clinical Practice: Beyond Recurrent C. difficile
Jessica R. Allegretti, MD, MPH
Evaluate the current understanding of the human microbiome and determine if we are able to test it, manipulate it, and apply our understanding to clinical practice.

CRC Screening: Consensus and Controversy in Special U.S. Populations
Aasma Shaukat, MD, MPH, FACG
Analyze the current status of CRC prevention in the U.S., including screening options in special populations, strategies to improve screening participation, and recent changes in guidelines, such as earlier screening for African American patients and recent American Cancer Society guidelines for beginning screening for all populations at age 45.

SUDD and SCAD: New Entities in the Spectrum of Diverticular Disease – Recognition and Management
Brennan M. Spiegel, MD, MSHS, FACG
Summarize new thinking about the role of antibiotics for acute diverticulitis and care of patients with symptomatic uncomplicated diverticular disease (SUDD) and segmental colitis associated with diverticular disease (SCAD).

SESSION 5: IBD
Moderator: Anne G. Tuskey, MD, FACG

Update on Biologics and Novel Therapeutics in IBD
Aline Charabaty, MD
Critically analyze the available data supporting biologics and novel therapeutics in IBD and provide guidance in choosing the appropriate treatment option in clinical practice.

Management of Perianal Disease
Susan Galandiuk, MD, FACG, FASCRS, FACS
Describe the treatment options available for complicated perianal disease.

Pain Management in IBD
Laurie A. Keefer, PhD
Recognize the impact of chronic pain in the management of IBD and outline effective treatment strategies to better manage pain.
SESSION 6: VGS-SPONSORED SYMPOSIUM: INNOVATION IN ENDOSCOPY
 Moderator: Andrew Y. Wang, MD, FACG, and Tilak U. Shah, MD, MHS

Introduction to the Endoscopy Experience in Virginia Centers
Alvin M. Zfass, MD, MACG
Discuss the beginnings and development of gastrointestinal endoscopy in Virginia and the role of the Virginia Gastroenterological Society in promoting the practice of endoscopy in Virginia and in the United States.

Colorectal Lesion Assessment: Choosing the Best Therapeutic Approach
David A. Johnson, MD, MACG
Describe endoscopic best practices regarding colorectal lesion assessment, in particular the Paris classification and dye-based and electronic chromoendoscopy classifications, and discuss features that might predict colorectal submucosal invasion and determine the appropriate intervention.

Colorectal Resection – Tips for Optimal Polypectomy, Mucosal Resection, and Dissection
Tilak U. Shah, MD, MHS
Identify the indications, risks, and techniques for endoscopic mucosal resection which may be useful to general gastroenterologists as well as to therapeutic endoscopists.

Upper GI Lesions: Assessment and Resection
Andrew Y. Wang, MD, FACG
Explain the endoscopic approach to assessing mucosally-derived neoplastic lesions in the esophagus, stomach, and duodenum and describe which types of endoscopic resection (EMR, ESD) are most applicable to certain lesions in the upper GI tract according to the location and lesion characteristics.

State-of-the-Art Presentation: Submucosal, Extraluminal, and Full-Thickness Endoscopy: Where Does This Fit in GI and Who Should Be Doing It?
Amrita Sethi, MD
Identify the forefront of endoscopic resection therapy and understand the benefits and pitfalls associated with submucosal, extraluminal, and full-thickness resection techniques.

SESSION 7: OBESITY SYMPOSIUM
 Moderator: Shelby A. Sullivan, MD, FACG

Dietary Approach in Medical Weight Loss
Shelby A. Sullivan, MD, FACG
Discuss the rationale, pros, and cons of a variety of dietary weight loss options utilized in medical programs.

Update on Pharmacologic Therapies in Weight Loss
Allan Hardy, MD
Compare the currently available pharmacologic weight loss therapies, their indications, contraindications, and potential adverse effects.

How to Manage NASH in the Obesity Epidemic
Zobair M. Younossi, MD, MPH, FACG
Describe the best approach to distinguishing between patients with NAFLD, NASH, and advanced fibrosis, and treatment strategies used in a fatty liver clinic in 2019.

Endoscopic Therapies for Obesity
Dilhana Badurdeen, MBBS, MD
Recognize the various options for the endoscopic treatment of obesity, and the benefits and limitations of each.

Does the Microbiome Influence Risk for Obesity?
Eamonn M. M. Quigley, MD, MACG
Identify the role of the microbiome in obesity and weight loss resistance, along with treatment strategies under investigation.

Practice Management: Pearls and Pitfalls in Setting Up Your GI Medical Weight Loss Clinic
Shelby A. Sullivan, MD, FACG
Develop procedures and processes for a GI medical weight loss program, including the practice model, methods of delivering care, financial outlook, growth, ancillary services, and challenges in a procedure-driven GI environment.